SecSonar.com

X4 Pharmaceuticals, Inc. (XFOR)

X4 Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

X4 Pharmaceuticals, Inc. (XFOR) is a Biotechnology company based in US with a market capitalization of $402.3M. Free cash flow was negative at -$88.6M. This page tracks XFOR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 143 employees · IPO Nov 16, 2017

Valuation

Valuation & price

$3.94 · as of May 17, 2026 · -15.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.16

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$4.66$3.04$1.43Jul 25Dec 25Jun 26Jul 7, 25$1.69Jul 9, 25$1.66Jul 11, 25$1.43Jul 15, 25$1.47Jul 17, 25$1.49Jul 21, 25$1.53Jul 23, 25$1.50Jul 25, 25$1.82Jul 29, 25$1.93Jul 31, 25$1.68Aug 4, 25$1.58Aug 6, 25$1.58Aug 8, 25$1.49Aug 12, 25$2.58Aug 14, 25$3.14Aug 18, 25$2.49Aug 20, 25$2.80Aug 22, 25$3.92Aug 27, 25$4.23Aug 29, 25$3.76Sep 3, 25$3.12Sep 5, 25$3.50Sep 9, 25$3.28Sep 11, 25$3.30Sep 15, 25$2.99Sep 17, 25$3.04Sep 19, 25$3.17Sep 23, 25$3.45Sep 25, 25$3.38Sep 29, 25$3.35Oct 1, 25$3.62Oct 3, 25$3.48Oct 7, 25$3.44Oct 9, 25$3.43Oct 13, 25$3.06Oct 16, 25$2.97Oct 20, 25$3.14Oct 22, 25$3.10Oct 24, 25$3.80Oct 28, 25$3.81Oct 30, 25$3.99Nov 3, 25$4.09Nov 5, 25$3.55Nov 7, 25$3.71Nov 11, 25$3.53Nov 13, 25$3.73Nov 17, 25$3.66Nov 19, 25$3.65Nov 21, 25$3.75Nov 25, 25$3.80Nov 28, 25$3.64Dec 2, 25$3.20Dec 5, 25$3.98Dec 9, 25$3.64Dec 11, 25$3.88Dec 15, 25$3.76Dec 17, 25$3.51Dec 19, 25$3.60Dec 23, 25$4.12Dec 26, 25$4.50Dec 30, 25$4.16Jan 2, 26$3.89Jan 6, 26$3.96Jan 8, 26$4.04Jan 12, 26$3.90Jan 14, 26$3.77Jan 16, 26$3.70Jan 21, 26$3.75Jan 23, 26$3.70Jan 28, 26$3.62Jan 30, 26$3.70Feb 3, 26$4.00Feb 5, 26$3.66Feb 9, 26$3.55Feb 11, 26$3.43Feb 13, 26$3.41Feb 18, 26$2.99Feb 20, 26$3.16Feb 24, 26$3.39Feb 26, 26$3.25Mar 2, 26$3.40Mar 4, 26$3.50Mar 6, 26$3.76Mar 10, 26$4.66Mar 12, 26$3.88Mar 16, 26$3.56Mar 19, 26$4.17Mar 23, 26$4.07Mar 25, 26$4.09Mar 27, 26$4.04Mar 31, 26$4.13Apr 2, 26$4.24Apr 7, 26$3.73Apr 9, 26$4.07Apr 13, 26$4.13Apr 15, 26$4.33Apr 17, 26$4.29Apr 21, 26$4.17Apr 23, 26$4.28Apr 27, 26$4.21Apr 29, 26$4.10May 1, 26$4.19May 5, 26$4.20May 8, 26$4.43May 12, 26$4.34May 14, 26$4.00May 18, 26$3.68May 20, 26$3.77May 22, 26$4.04May 27, 26$4.03May 29, 26$4.31Jun 2, 26$4.04Jun 4, 26$4.01Jun 8, 26$3.71Jun 10, 26$3.73Jun 12, 26$4.00Jun 16, 26$4.04Jun 18, 26$4.22Jun 23, 26$4.00Jun 29, 26$4.13
$1.4252-week range$4.66
Loading valuation history…

Fundamentals

Key fundamentals

$402.3M

Market cap

—

Revenue growth (YoY)

82.2%

Gross margin

-$88.6M

Free cash flow (USD)

-$175.7M

Net debt

Net cash position

531.0%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$3.0MFY 2021$0.00FY 2022$0.00FY 2023$0.00FY 2024$2.6MFY 2025$35.1M
$0$35.1M

Free cash flow by year

2016 → 2025

FY 2016$-21.7MFY 2017$-27.9MFY 2018$-25.4MFY 2019$-48.2MFY 2020$-60.2MFY 2021$-71.5MFY 2022$-77.2MFY 2023$-96.6MFY 2024$-138.2MFY 2025$-88.6M
-$21.7M-$88.6M

Gross margin by year

2024 → 2025

FY 202468.8%FY 202582.2%
68.8%82.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventDirector AppointmentJul 1, 2026Filing
  • 8-K eventEquity Incentive Plan AmendedMay 13, 2026Filing
  • 8-K eventEquity Incentive Plan UpdateMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • FinancingSecurities RegistrationMay 6, 2026Filing

Questions

Frequently asked questions

What is X4 Pharmaceuticals, Inc.'s market cap?

X4 Pharmaceuticals, Inc. (XFOR) has a market capitalization of $402.3M.

What is XFOR's P/E ratio?

A meaningful P/E ratio is not available for XFOR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is XFOR's price-to-book (P/B) ratio?

XFOR trades at 2.16 times book value per share.

Are insiders buying XFOR stock?

SEC Form 4 filings show no open-market insider buys at X4 Pharmaceuticals, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

LYEL

Lyell Immunopharma, Inc.

$406.2M

VNDA

Vanda Pharmaceuticals Inc.

$391.5M

FULC

Fulcrum Therapeutics, Inc.

$377.7M

ADCT

ADC Therapeutics S.A.

$433.1M

PTN

Palatin Technologies, Inc.

$368M

CCCC

C4 Therapeutics, Inc.

$367.8M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.